Ceribell reported a trio of milestones alongside its Q2 results. CMS granted a New Technology Add-on Payment of up to $2,171 per Medicare case for its Delirium Monitor, and the FDA cleared new epileptiform detection and artifact-reduction algorithms for its cloud portal. Revenue rose 33% to $28.1 million, and the company raised full-year guidance. Ceribell makes a rapid, portable EEG headband that lets non-specialists assess seizures and delirium at the bedside, and is building its seizure-detection base into a broader brain-monitoring platform.